CervoMed Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:CRVO) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 43.08 M38.58 M38.08 M30.61 M22.88 M15.11 M 負債合計 3.88 M3.94 M4.64 M4.6 M4.66 M4.5 M 純資産合計 39.2 M34.63 M33.44 M26.01 M18.22 M10.62 M 負債および純資産合計 43.08 M38.58 M38.08 M30.61 M22.88 M15.11 M 有利子負債合計 —————— 純負債 ——————

ニュース

Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

H.C. Wainwrightが学会データを受けてCervoMed株の投資判断を維持

H.C. Wainwright reiterates CervoMed stock rating on conference data

CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

CervoMed、レビー小体型認知症の第3相試験で50mg投与量を設定

CervoMed sets 50mg dose for phase 3 dementia trial

Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?

CervoMedのneflamapimod、英国ALS試験プラットフォームに選定

CervoMed’s neflamapimod selected for UK ALS trial platform